Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
MALT1
100%
Anticancer Immune Response
100%
Breast Cancer
100%
Immune Microenvironment
100%
Triple-negative Breast Cancer
90%
G Protein-coupled Receptor
70%
MALT1 Protease
30%
Signaling Axis
20%
Protease Activity
20%
Pharmaceutics
20%
Immune Cells
20%
Progesterone Receptor
10%
BCL10
10%
Hispanic Women
10%
Microenvironment
10%
Ex Vivo System
10%
Signaling Complex
10%
Carcinoma
10%
LPAR1
10%
Angiotensin II Type 1 Receptor (AT1R)
10%
Clinical Outcomes
10%
Effector T Cells
10%
Difficult-to-treat
10%
Estrogen Receptor
10%
Human Patients
10%
Therapeutic Implications
10%
CARMA3
10%
Breast Cancer Cases
10%
Immune Suppressed
10%
Tumor-infiltrating Immune Cells
10%
Triple-negative Breast Cancer Cells
10%
Cell-to-cell
10%
CBM Signalosome
10%
Invasive Breast Cancer
10%
Immune Suppression
10%
Beneficial Effects
10%
Tumor Cells
10%
African American Women
10%
Tumor Immune Microenvironment
10%
Human Epidermal Growth Factor Receptor 2 (HER2)
10%
Therapeutic Strategies
10%
Tumor Immunity
10%
Targeted Therapy
10%
New Drug Targets
10%
Tumor Immune Suppression
10%
Aggressive Breast Cancer
10%
Regulatory T Cells
10%
Cancer Cells
10%
Immunoreactivity
10%
Effector Proteins
10%
Treg Function
10%
Overexpression
10%
Biochemistry, Genetics and Molecular Biology
MALT1
100%
Immune Microenvironment
100%
G Protein Coupled Receptor
53%
Protease
23%
Immunocompetent Cell
23%
Cancer Cell
15%
Prevalence
7%
T Cell
7%
Targeted Therapy
7%
LPAR1
7%
Tumor Immune Microenvironment
7%
Regulatory T Cell
7%
BCL10
7%
Progesterone Receptor
7%
Immunoreactivity
7%
Experimental Model
7%
signalosome
7%
Tumor Immunity
7%
Reprogramming
7%